FIRST-QUARTER 2024 SALES
April 18, 2024 01:30 ET
|
Forvia
NANTERRE (FRANCE)APRIL 18, 2024 FIRST-QUARTER 2024 SALES Q1 2024 SALES OUTPERFORMANCE OF 390bps TO REACH €6.531bnROBUST ORDER INTAKE OF €6.5bn, UP €1bn vs. Q1 2023 in €m Q1 2023Currency...
Gildan Activewear CEO Vince Tyra provides key focus strategic priorities
April 15, 2024 16:18 ET
|
Gildan Activewear, Inc.
Company Reconfirms 2024 Full Year GuidanceAnnounces Preliminary Q1 2024 RevenueCompany to Host Investor Day in Fall 2024 MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (GIL;...
Hooker Furnishings Reports Improved Profitability in 2024 Fiscal Year
April 11, 2024 06:00 ET
|
Hooker Furnishings Corporation
MARTINSVILLE, Va., April 11, 2024 (GLOBE NEWSWIRE) -- Hooker Furnishings Corporation (NASDAQ-GS: HOFT) (the “Company” or “HFC”), a global leader in the design, production, and marketing of home...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
April 01, 2024 16:05 ET
|
Xilio Therapeutics, Inc.
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
March 28, 2024 07:05 ET
|
Xilio Therapeutics, Inc.
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and...
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
March 28, 2024 07:00 ET
|
Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
-- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers -- FOSTER CITY, Calif....
Lands’ End Announces Fourth Quarter and Full Year Fiscal 2023 Results
March 27, 2024 06:45 ET
|
Lands' End, Inc.
Increases Gross Profit by 13.5% and Gross Margin by 550 basis points compared to the Fourth Quarter Fiscal 2022Provides Fiscal 2024 Outlook DODGEVILLE, Wis., March 27, 2024 (GLOBE NEWSWIRE) --...
CHECKLIGHT® from CISO Global Proven to Reduce Cyber Loss, According to 2023 Measurement Data
March 19, 2024 08:30 ET
|
CISO Global
AI-powered Endpoint Detection and Response solution, backed by a $250,000 financial protection plan, significantly reduced the number and severity of cyber losses for enterprises Scottsdale,...
Vera Bradley Announces Fourth Quarter and Fiscal Year 2024 Results
March 13, 2024 08:00 ET
|
Vera Bradley, Inc.
Vera Bradley Announces Fourth quarter and Fiscal Year 2024 Results
The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results
March 07, 2024 16:20 ET
|
The Joint Corp.
- Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March...